ZEVRA THERAPEUTICS, INC. Annual Operating Income (Loss) in USD from 2013 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Zevra Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2013 to 2024.
  • Zevra Therapeutics, Inc. Operating Income (Loss) for the quarter ending March 31, 2025 was -$5.36M, a 73.8% increase year-over-year.
  • Zevra Therapeutics, Inc. Operating Income (Loss) for the twelve months ending March 31, 2025 was -$71.9M, a 25.5% decline year-over-year.
  • Zevra Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$87M, a 75.4% decline from 2023.
  • Zevra Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$49.6M, a 16.5% decline from 2022.
  • Zevra Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$42.6M, a 651% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.